EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
-2.54%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$969M
AUM Growth
+$969M
(-26%)
Cap. Flow
-$232M
Cap. Flow
% of AUM
-23.92%
Top 10 Holdings %
Top 10 Hldgs %
64.29%
Holding
82
New
14
Increased
14
Reduced
29
Closed
17
Top Buys
| 1 |
HCA Healthcare
HCA
|
$14M |
| 2 |
Bruker
BRKR
|
$13.8M |
| 3 |
Edwards Lifesciences
EW
|
$12.6M |
| 4 |
DexCom
DXCM
|
$11.6M |
| 5 |
Teleflex
TFX
|
$11M |
Top Sells
| 1 |
Insmed
INSM
|
$79.5M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$49.7M |
| 3 |
United Therapeutics
UTHR
|
$30.8M |
| 4 |
Bio-Techne
TECH
|
$26.2M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$21.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Guardant Health
GH
$8.41B
| $8.43M | 0.75% | +276,036 | New | +$8.43M |
|
27
Repligen
RGEN
$6.88B
| $7.78M | 0.69% | 54,066 -109,527 | -67% | -$15.8M |
|
28
Ionis Pharmaceuticals
IONS
$6.79B
| $7.51M | 0.67% | 214,952 -256,403 | -54% | -$8.96M |
|
29
Fortrea Holdings
FTRE
$894M
| $7.49M | 0.67% | 401,733 -56,234 | -12% | -$1.05M |
|
30
NewAmsterdam Pharma
NAMS
$2.71B
| $7.08M | 0.63% | 275,362 -31,995 | -10% | -$822K |
|
31
AstraZeneca
AZN
$248B
| $6.73M | 0.6% | +102,661 | New | +$6.73M |
|
32
Liquidia Corp
LQDA
$2.38B
| $6.72M | 0.6% | 571,305 +433,356 | +314% | +$5.1M |
|
33
Medpace
MEDP
$13.4B
| $6.33M | 0.56% | +19,049 | New | +$6.33M |
|
34
Xenon Pharmaceuticals
XENE
$2.98B
| $6.1M | 0.54% | +155,540 | New | +$6.1M |
|
35
MannKind Corp
MNKD
$1.41B
| $5.86M | 0.52% | 911,025 -1,081,479 | -54% | -$6.95M |
|
36
Humana
HUM
$36.5B
| $5.75M | 0.51% | 22,682 -11,178 | -33% | -$2.84M |
|
37
Henry Schein
HSIC
$8.44B
| $5.56M | 0.49% | +80,303 | New | +$5.56M |
|
38
Danaher
DHR
$147B
| $5.1M | 0.45% | 22,209 -16,220 | -42% | -$3.72M |
|
|
39
Syndax Pharmaceuticals
SNDX
$1.41B
| $4.54M | 0.4% | 343,400 -3,761,913 | -92% | -$49.7M |
|
|
PDCO
40
DELISTED
Patterson Companies, Inc.
PDCO
| $4.51M | 0.4% | +146,051 | New | +$4.51M |
|
41
Gossamer Bio
GOSS
$562M
| $4.5M | 0.4% | 4,978,458 | – | – |
|
42
Evolus
EOLS
$494M
| $4.23M | 0.38% | 383,045 -70,016 | -15% | -$773K |
|
43
Icon
ICLR
$13.8B
| $4.04M | 0.36% | 19,252 +5,584 | +41% | +$1.17M |
|
44
Supernus Pharmaceuticals
SUPN
$2.53B
| $3.82M | 0.34% | +105,581 | New | +$3.82M |
|
45
Avantor
AVTR
$9.18B
| $3.55M | 0.31% | 168,369 | – | – |
|
46
Puma Biotechnology
PBYI
$254M
| $3.04M | 0.27% | 996,102 -297,155 | -23% | -$906K |
|
|
TSVT
47
DELISTED
2seventy bio
TSVT
| $2.95M | 0.26% | 1,003,678 +5,599 | +0.6% | +$16.5K |
|
48
Merus
MRUS
$4.98B
| $2.87M | 0.25% | 68,258 | – | – |
|
|
MREO
49
Mereo BioPharma
MREO
$272M
| $2.72M | 0.24% | 777,890 | – | – |
|
50
Zai Lab
ZLAB
$3.68B
| $2.7M | 0.24% | 102,930 -32,289 | -24% | -$846K |
|